Coherus Oncology, Inc. Common Stock (CHRS) — Analysis Summary
Coherus Oncology, Inc. Common Stock (CHRS) has a market cap of $245.26M with year-over-year revenue growth of -84.2%. Net margin stands at 398.4%. The stock trades at a P/E ratio of 1.3.
Key Takeaways
- Revenue changed -84.2% year-over-year
- Net margin of 398.4%
- P/E ratio of 1.3
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, CHRS posted revenue growth of -84.2% and trades at a P/E of 1.3.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.